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1. INTRODUCTION {#mgg31244-sec-0005}
===============

Stable body weight maintenance is one of the key elements of human survival, which is achieved by the balance of intake and expenditure of energy. To keep this balance, control of food intake is a vital factor that involves a complex system of central as well as peripheral physiological signals (Abdalla, [2017](#mgg31244-bib-0001){ref-type="ref"}).

According to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐V), anorexia nervosa (AN) is defined as a disorder in which patients weigh less than minimally normal (adults) and less than minimally expected (children and adolescents) in the context of age, sex development, and physical health, and show persistent behavior that interferes with weight gain (Clarke, Weiss, & Berrettini, [2012](#mgg31244-bib-0018){ref-type="ref"}).

In acute cases, usual symptoms of AN patients include fatigue, dizziness, and syncope, while in chronic patients, all organs are affected because of malnutrition (Zipfel, Giel, Bulik, Hay, & Schmidt, [2015](#mgg31244-bib-0098){ref-type="ref"}).

AN is a complex and serious illness, affecting 0.9%--4% of women and 0.3% of men, with twin‐based heritability estimates of 50%--60%. The onset of the disease occurs mostly during adolescence, though onset before puberty is also not unusual, and women are sometimes diagnosed with AN at midlife or older adulthood (Watson et al., [2019](#mgg31244-bib-0093){ref-type="ref"}).

AN has the highest mortality rate among psychiatric disorders because it can result in significant medical complications (Moskowitz & Weiselberg, [2017](#mgg31244-bib-0071){ref-type="ref"}). A meta‐analysis reported a rough mortality rate of 5.1 deaths per 1,000 individuals per year (Arcelus, Mitchell, Wales, & Nielsen, [2011](#mgg31244-bib-0004){ref-type="ref"}).

AN is a multifactorial disorder, but there is a strong genetic component. For instance, it is known that those consanguineous of AN patients are more likely to have AN than the relatives of unaffected controls (Strober, Freeman, Lampert, Diamond, & Kaye, [2000](#mgg31244-bib-0088){ref-type="ref"}). Furthermore, twin and linkage studies indicate that genetic factors play a fundamental role (Devlin, Jones, Bacanu, & Roeder, [2002](#mgg31244-bib-0027){ref-type="ref"}; Klump, Miller, Keel, McGue, & Iacono, [2001](#mgg31244-bib-0054){ref-type="ref"}; Kortegaard, Hoerder, Joergensen, Gillberg, & Kyvik, [2001](#mgg31244-bib-0056){ref-type="ref"}).

Treatment of AN is difficult, which accounts for the high morbidity and mortality of AN. Medication options are still under trial and research is going on to identify drugs that can target the pathway associated with this disorder.

The aim of this review is to summarize the present knowledge on the molecular and genetic determinants of AN through literature search, and to propose genetic testing for AN that includes those genes that might carry rare variants predisposing to AN and genes that, when mutated, cause syndromic conditions in which anorexia is one of the features.

2. MOLECULAR PATHWAYS INVOLVED IN ANOREXIA NERVOSA {#mgg31244-sec-0006}
==================================================

Among all species, food intake is a conserved behavioral characteristic that involves various biological systems, such as the serotonergic pathway, which is a conserved neural system that controls the feeding behavior of humans and other mammals, such as rodents.

2.1. Serotonin pathway {#mgg31244-sec-0007}
----------------------

Serotonin or 5‐hydroxytryptamine (5‐HT) receptors are crucial for the regulation of molecular substrates required for survival, such as food intake, prevention of depressive states, control of anxiety, as well as fear of novelty, learning, memory, locomotion, and peripheral functions (i.e., gastrointestinal peristalsis). Any dysregulation in the 5‐HT systems results in symptoms similar to AN. The reuptake of 5‐HT was observed to be increased by the administration of estrogen, which alters the mRNA as well as the protein levels of various serotonin markers and reduces the breakdown of 5‐HT. Persistent external stress could limit neuronal plasticity associated with the serotonin pathway and predispose to anorexia (Compan, [2017](#mgg31244-bib-0019){ref-type="ref"}; Lokuge, Frey, Foster, Soares, & Steiner, [2011](#mgg31244-bib-0061){ref-type="ref"}). Similarly, AN patients might also show abnormalities in the *HTR1D* (serotonin 1D) gene (OMIM \*182133) (Brown et al., [2007](#mgg31244-bib-0013){ref-type="ref"}).

2.2. Opioid and dopamine pathways {#mgg31244-sec-0008}
---------------------------------

Opioid peptides are derived from pro‐opiomelanocortin maturation and help regulate the balance between energy intake and expenditure through reward‐mediated behavior. Opioid peptides are expressed in the paraventricular nucleus of the hypothalamus, ventromedial hypothalamus, amygdala, nucleus accumbens, and the forebrain regions (Hasan & Hunaid, [2011](#mgg31244-bib-0045){ref-type="ref"}).

Dopamine is a neuromodulating catecholamine found throughout the mammalian central nervous system, and midbrain dopamine‐containing neurons regulate emotional behavior, natural motivation, reward, and cognitive function (Chao & Nestler, [2004](#mgg31244-bib-0016){ref-type="ref"}).

Several studies show that AN might be caused by an altered dopamine pathway. For instance, patients with AN have low levels of the major dopamine metabolite, homovanillic acid, in their cerebrospinal fluid (Kaye, Ebert, Gwirtsman, & Weiss, [1984](#mgg31244-bib-0051){ref-type="ref"}).

According to another study, dieting in association with high levels of exercise promotes an increase in dopamine, that in turn facilitates rewarding behaviors such as diet and exercise, that can become habits similar to drug dependency or self‐starvation (Södersten, Nergårdh, Bergh, Zandian, & Scheurink, [2008](#mgg31244-bib-0086){ref-type="ref"}). Abnormalities in the dopamine pathway can also cause hyperactive motor behavior along with behavioral inhibition (Klenotich, Ho, McMurray, Server, & Dulawa, [2015](#mgg31244-bib-0053){ref-type="ref"}; Moskowitz & Weiselberg, [2017](#mgg31244-bib-0071){ref-type="ref"}).

2.3. Vitamin D3 as a neurosteroid {#mgg31244-sec-0009}
---------------------------------

Vitamin D3 is a steroid hormone recognized to have many extra‐skeletal roles, and serum vitamin D3 deficiency has been correlated to obesity and diabetes. It is known that vitamin D3 modulates peroxisome proliferator‐activated receptor gamma (PPARγ), involved in inflammation related to the diet (Tasegian et al., [2016](#mgg31244-bib-0090){ref-type="ref"}). A cross‐sectional study was done to meta‐analyze the vitamin D3 parameters in AN patients relative to healthy controls. Results showed that the metabolite of vitamin D3 (25‐hydroxyvitamin D), as well as vitamin D3 levels of AN patients, were significantly lower without proper supplementation (Giollo et al., [2017](#mgg31244-bib-0036){ref-type="ref"}; Veronese et al., [2015](#mgg31244-bib-0091){ref-type="ref"}).

Patients with AN have a vitamin D3 deficiency that leads to defects in bone mineralization. Furthermore, vitamin D3 can also play a role as a neurosteroid. The connection between vitamin D3 and AN might be its ability to regulate neurotrophic factors, provide neuroprotection, modulate neurotransmission, and contribute to synaptic plasticity. Studies in rats showed that vitamin D3 is present already in the early phases of brain development. It is interesting to note that the initial expression of the vitamin D receptors in the rat brain corresponds with the appearance of dopaminergic neurons within the mesencephalon, but the vitamin D receptors are also expressed within the dopaminergic neurons in the adult substantia nigra (Groves, McGrath, & Burne, [2014](#mgg31244-bib-0040){ref-type="ref"}).

It has been observed that mice lacking vitamin D receptor have increased anxiety (Kalueff, Lou, Laaksi, & Tuohimaa, [2004](#mgg31244-bib-0050){ref-type="ref"}); this is consistent with the role of vitamin D3 in the repression of serotonin reuptake, transport, and degradation. The diminished brain levels of serotonin and vitamin D3 could result in social behavior changes associated with autism spectrum disorders and depression (Sabir et al., [2018](#mgg31244-bib-0080){ref-type="ref"}). Finally, vitamin D3 role in AN might be associated with the increase in the expression of genes involved in estrogen biosynthesis. In fact, vitamin D3 is a powerful regulator of sex steroid hormone production in porcine granulosa cells via the modulation of steroidogenic enzymes (Hong et al., [2017](#mgg31244-bib-0046){ref-type="ref"}).

2.4. Appetite‐regulating hormones {#mgg31244-sec-0010}
---------------------------------

The regulation of body weight relies on both central and peripheral stimuli. The central regulation of appetite is due to the hypothalamus, which integrates signals coming from the periphery. Although some variants that affect genes expressed in the hypothalamus have been linked to obesity, it is also known that lesions in the lateral hypothalamus can cause a dramatic reduction of food intake in rats (Anand & Brobeck, [1951](#mgg31244-bib-0002){ref-type="ref"}).

The central part of the hypothalamus (the arcuate nucleus) integrates signals regarding food intake and energy expenditure (Miller, [2017](#mgg31244-bib-0067){ref-type="ref"}). This regulation is based on the expression of neuropeptides and their receptors. Other signals that participate in the regulation of energy intake and expenditure come from the periphery of the organism and can be produced by the adipose tissue, such as leptin, or from the gut, such as cholecystokinin (CCK) and ghrelin (Miller, [2017](#mgg31244-bib-0067){ref-type="ref"}).

The gut has specific endocrine cells that release various hormones in response to nutrient intake. Postprandial satiety is regulated by the communication between gut and hypothalamus, involving appetite hormones. These appetite modulators comprise both orexigenic and anorexigenic hormones, such as ghrelin, leptin, CCK, peptide YY (PYY), pancreatic polypeptide (PP), oxyntomodulin (OXM), and glucagon‐like peptide (GLP)‐1. After stimulation, anorexigenic peptides are released while the levels of the orexigenic peptide ghrelin reduce (Perry & Wang, [2012](#mgg31244-bib-0075){ref-type="ref"}).

Ghrelin is produced in the stomach and pancreatic cells and exhibits a wide range of effects on feeding behavior, reward mechanisms, reproduction, and growth, and results in positive energy balance (Perry & Wang, [2012](#mgg31244-bib-0075){ref-type="ref"}). Ghrelin has a link with AN. This is evident from numerous animal studies in which ghrelin activates the reward pathways in the brain, which in turn contribute to AN and other addictive disorders, such as alcoholism (Perello & Dickson, [2015](#mgg31244-bib-0074){ref-type="ref"}).

Leptin is produced by adipocytes and exhibits a powerful effect on food intake and energy expenditure. Leptin acts both peripherally and centrally by reducing the appetite and creating an overall negative energy balance (Steiner & Romanovsky, [2007](#mgg31244-bib-0087){ref-type="ref"}). In a study by Monteleone et al. ([2005](#mgg31244-bib-0070){ref-type="ref"}), the serum level of leptin was reported to be significantly decreased in AN patients but only moderately increased in obese patients. In the hypothalamus, leptin acts through cell surface receptors, mediated by feeding regulators like neuropeptide Y (NPY) (Palmiero Monteleone et al., [2005](#mgg31244-bib-0070){ref-type="ref"}).

NPY is a member of the pancreatic polypeptide family, and its levels reflect the nutritional status of the body, and during fasting, NPY levels increase, then decrease after re‐feeding (Beck, [2006](#mgg31244-bib-0006){ref-type="ref"}).

The pancreatic polypeptide (PPY) is secreted postprandially, and its peripheral administration decreases appetite along with weight loss through inhibition of the arcuate hypothalamic nucleus expression of NPY/AGRP (De Silva & Bloom, [2012](#mgg31244-bib-0026){ref-type="ref"}).

Similarly, CCK acts with the help of its receptor and causes short‐term food intake inhibition (Cummings & Overduin, [2007](#mgg31244-bib-0022){ref-type="ref"}), and GLP‐1 increases satiety and decreases food intake (Shah & Vella, [2014](#mgg31244-bib-0082){ref-type="ref"}). OXM, which acts through GLP‐1 receptor, causes short‐term food intake suppression and reduction of plasma levels of ghrelin (Perry & Wang, [2012](#mgg31244-bib-0075){ref-type="ref"}).

2.5. Endocannabinoid pathway {#mgg31244-sec-0011}
----------------------------

The endocannabinoid system plays a significant role in the regulation of appetite. This endogenous cannabinoid neuromodulator system includes two cannabinoid receptors, CB1 and CB2, along with endogenous ligands like anandamide (N‐arachidonoylethanolamine), 2‐arachidonoylglycerol, as well as the enzymes contributing to their synthesis or degradation, such as monoacylglycerol lipase (MAGL), fatty acid amide hydrolase (FAAH), N‐acyl phosphatidylethanolamine phospholipase D (NAPE‐PLD), and diacylglycerol lipase (DAGL) (Berry & Mechoulam, [2002](#mgg31244-bib-0010){ref-type="ref"}; Doris, Millar, Idris, & O'Sullivan, [2019](#mgg31244-bib-0031){ref-type="ref"}). Animal models showed that endocannabinoids enhance feeding; in fact, the blockade of cannabinoid receptor CB1 suppresses eating (Hao, Avraham, Mechoulam, & Berry, [2000](#mgg31244-bib-0044){ref-type="ref"}). The CB1 knockout (KO) mice eat less than their normal littermates after starvation (Di Marzo et al., [2001](#mgg31244-bib-0065){ref-type="ref"}). Furthermore, cannabinoids are known to induce "reward" effects, such as the feeling of pleasure after eating tasty food (Di Marzo et al., [2001](#mgg31244-bib-0065){ref-type="ref"}).

Genetic variants in the *CNR1* (OMIM \*114610) gene, which encodes the CB1 (cannabinoid 1) receptor, might contribute significantly to the susceptibility to AN. This hypothesis of the potential association of *CNR1* variants with AN was further investigated after the identification in this gene of a triplet repeat marker in a family‐based study (Siegfried et al., [2004](#mgg31244-bib-0084){ref-type="ref"}). The involvement of *CNR1* trinucleotide repeats might be one of the explanations for the non‐Mendelian inheritance of AN, though more functional studies are needed to prove the differential effect of the various (AAT)~n~ repeats on the CB1 receptor.

The role of the cannabinoid receptors is also supported by studies performed on anandamide (also known as N‐arachidonoylethanolamine), a fatty acid neurotransmitter derived from the arachidonic acid and degraded by the FAAH enzyme. In particular, one of the effects of anandamide might be the modulation of neuronal structure. In fact, by binding to CB1R, anandamide inhibits neuronal differentiation and causes the retraction of neurites (Rueda, Navarro, Martínez‐Serrano, Guzmán, & Galve‐Roperh, [2002](#mgg31244-bib-0079){ref-type="ref"}). The differentiation, induced by nerve growth factor (NGF), of PC12 cells (expressing the anandamide receptor CB1) was inhibited by anandamide administration, which blocks the activation of the NGF receptor. Thus, anandamide plays a key role in the establishment of synaptic plasticity (Goodfellow & Glass, [2009](#mgg31244-bib-0037){ref-type="ref"}). This reduction of neural plasticity caused by anandamide might explain why levels of anandamide are significantly enhanced in the plasma of anorexic women. Moreover, circulating anandamide levels were significantly and inversely correlated with plasma leptin concentrations in both healthy controls and anorexic women (Palmiero Monteleone et al., [2005](#mgg31244-bib-0070){ref-type="ref"}).

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide. The main target of PEA is the peroxisome proliferator‐activated receptor α (PPARα). PEA can also bind to cannabinoid‐like G‐coupled receptors GPR55 and GPR119. The anorectic action of exogenous PEA is mediated by the activation of the transcription factor PPARα in the small intestine (Hansen, Kleberg, & Hassing, [2015](#mgg31244-bib-0043){ref-type="ref"}). In mouse, intestinal concentration of PEA decreases in response to high‐fat feeding, and it was speculated that PEA might function as a biosensor for dietary fat. PEA, after the activation of PPARα, brings the signal further through the vagus nerve to the brain (Di Guida, [2017](#mgg31244-bib-0029){ref-type="ref"}). In underweight AN patients, plasma PEA concentration increases after exposure to a non‐favorite meal and progressively decrease after eating it, whereas plasma concentrations of PEA progressively decrease in hedonic eating (Monteleone et al., [2015](#mgg31244-bib-0068){ref-type="ref"}).

3. GENETICS OF ANOREXIA NERVOSA {#mgg31244-sec-0012}
===============================

AN has a strong genetic component. It sometimes has a familial presentation; there is a fourfold increase in susceptibility to AN among family members, and female relatives of AN patients have an 11 times greater risk of disease compared to the normal population (Zipfel et al., [2015](#mgg31244-bib-0098){ref-type="ref"}). Studies have shown that genes contribute more than 50% to 74% of AN developing risk (Moskowitz & Weiselberg, [2017](#mgg31244-bib-0071){ref-type="ref"}), and monozygotic twins have a higher likelihood of developing AN then dizygotic twins (Yilmaz, Hardaway, & Bulik, [2015](#mgg31244-bib-0097){ref-type="ref"}). Generally, when AN cases are defined using strict criteria, the heritability is higher compared to the heritability of broadly defined "subsyndromic" AN cases.

3.1. Rare variants with Mendelian segregation {#mgg31244-sec-0013}
---------------------------------------------

In one recent study, using whole‐exome analysis in two independent families with male individuals with AN, the authors found variants in the neuronatin (*NNAT*) gene (OMIM \*603106) in both probands: one nonsense variant (p.Trp33\*) and one rare variant in the 5′UTR, respectively (Lombardi et al., [2019](#mgg31244-bib-0062){ref-type="ref"}). Afterward, to confirm their data, a screening of the *NNAT* was conducted in a cohort of eight male and 144 female individuals with AN, and a further 11 *NNAT* variants were found, showing that 40% and 6% of male and female AN individuals carried an *NNAT* variant, respectively. The protein encoded by *NNAT* is a proteolipid that might be involved in the regulation of ion channels during brain development. The encoded protein might also participate in the maintenance of segment identity in the hindbrain and pituitary development (Lombardi et al., [2019](#mgg31244-bib-0062){ref-type="ref"}).

In a study published in 2014 (Scott‐Van Zeeland et al., [2014](#mgg31244-bib-0081){ref-type="ref"}), the authors analyzed a series of 152 candidate genes involved in feeding behaviors, dopamine function, serotonin signaling, and genes previously associated using GWAS, such as *OPRD1* (OMIM \*165195) and *EPHX2* (OMIM \*132811), to identify genetic variants that contribute to AN. DNA sequencing was performed in a cohort of about 700 AN, and rare *EPHX2* variants were identified as significantly associated with AN (Scott‐Van Zeeland et al., [2014](#mgg31244-bib-0081){ref-type="ref"}).

The *EPHX2* encodes an epoxide hydrolase found in both the cytosol and peroxisomes and involved in cholesterol metabolism. The protein is expressed in neural tissues relevant to AN and *EPHX2* transcription might be induced by sex hormones and is regulated by the hypothalamic‐pituitary‐gonadal axis. This would account for the potential role of this gene in the etiology or maintenance of AN. Many studies have reported high serum cholesterol levels in malnourished individuals suffering from AN (Scott‐Van Zeeland et al., [2014](#mgg31244-bib-0081){ref-type="ref"}). In the same study, the authors reported that *ESR2* (OMIM \*601663), encoding the estrogen receptor 2, might harbor variants associated with AN. This association is interesting because most of the AN cases are female. Additionally, these results are consistent with previous research suggesting that estrogens and their receptor are linked with the etiology of AN (Scott‐Van Zeeland et al., [2014](#mgg31244-bib-0081){ref-type="ref"}).

Another study combined exome sequencing, whole‐genome sequencing, and linkage analysis to examine two families with recurrence of eating disorders, especially AN. In the first pedigree, the best candidate to explain the predisposition to eating disorders was a missense variant co‐segregating with the affected family members in the *ESRRA* (estrogen‐related receptor alpha) (OMIM \*601998), while a potentially damaging mutation in the *HDAC4* (histone deacetylase 4) (OMIM \*605314) was reported in the second pedigree (Cui et al., [2013](#mgg31244-bib-0021){ref-type="ref"}). These genes play a significant role in the estrogen system. Thus, this would explain why there is a majority of affected female family members. *ESRRA* encodes a nuclear receptor that has sequence homology with estrogen receptors and plays a role in energy balance as well as metabolism. *HDAC4* encodes a histone deacetylase and is also linked to the development and function of central nervous system. Further transcriptional studies revealed that expression of the HDAC4 deacetylase repressed the transcription of ESRRA‐induced target genes, whereas ESRRA and HDAC4 exhibited interaction in both in vivo and in vitro studies. These results suggest that the identified variants cause a decrease in the activity of ESRRA and an increase in the likelihood of developing AN (Sild & Booij, [2019](#mgg31244-bib-0085){ref-type="ref"}).

In a 2017 study, a whole‐exome sequencing approach was used to analyze 38 individuals with restricting AN and 55 individuals with AN associated with binge/purge behaviors (Lutter et al., [2017](#mgg31244-bib-0063){ref-type="ref"}). The genes carrying predicted damaging variants mainly belonged to three pathways: (a) neuropeptide hormone signaling, (b) inflammatory pathway, and (c) cholinergic neurotransmission. Consistently, most of the identified neuropeptides regulate appetite and body weight homeostasis. An in silico approach then evaluated the pathogenicity of the identified variants. One variant in *NTS* (OMIM \*162650), the gene encoding the neuropeptide transmitter neurotensin, disrupts a motif required for the generation of mature neuropeptide neurotensin through cleavage. Three other *NTS* variants occur in the portion of the propeptide that is maturated to generate neuromedin N, which also binds the neurotensin receptor. Furthermore, the authors found one individual who harbored a truncating variant in the neurotensin receptor 1 (*NTSR1*) gene (OMIM \*162651). Of note, this variant co‐segregated with the AN phenotype in the daughter and granddaughter (Lutter et al., [2017](#mgg31244-bib-0063){ref-type="ref"}).

Finally, 245 genes were identified with damaging variants at a significantly higher rate than predicted in the binge‐eating AN cohort. *UNC80* (OMIM \*612636) had the most damaging variants in the binge‐eating group; the encoded protein is a component of the nonselective sodium leak channel (NALCN), an ion channel regulated by the peptide neurotransmitter substance P and neurotensin. Another important neuropeptide, preproglucagon (synthesized from the *GCG*, OMIM \*138030), has been found to carry two variants. This protein is proteolytically cleaved to generate several neuropeptides in the brain. The first variant in *GCG* eliminates an arginine required for the generation of oxyntomodulin, while the second variant replaces an arginine within the cleavage site required for generation of GLP‐1. Both oxyntomodulin and GLP‐1 are agonists for the GLP‐1 receptor. Finally, the authors also detected predicted damaging variants in both *BDNF* (OMIM \*113505) and its receptor, *NTRK2* (OMIM \*600456). Of note, *BDNF* and *NTRK2* have previously been implicated in food intake and body weight regulation (Lutter et al., [2017](#mgg31244-bib-0063){ref-type="ref"}).

Two very recent articles by Bienvenu et al. in 2019 support the multigenic etiology of AN. In the first study, the authors sequenced the whole exome of one family and found three ultra‐rare deleterious variants within the *DRD4* (OMIM \*126452), *NMS*, and *CCKAR* (OMIM \*118444) (Bienvenu et al., [2019b](#mgg31244-bib-0012){ref-type="ref"}). *DRD4* encoded a dopamine receptor and carried the p.Leu356Arg rare variant in the highly conserved region of one of its intracellular loops in all three affected members of the family. *NMS* encodes a 36‐amino acid pre‐proprotein (neuromedin S) that is proteolytically processed to generate a neuropeptide that plays a role in the regulation of anorexigenic action, and stimulation of oxytocin and vasopressin release. This protein carried a p.Met1Thr variant in all affected members. Finally, *CCKAR*, which encodes a CCK‐binding receptor, had a rare variant, p.Cys387Tyr, in the cytoplasmic C‐terminal region that segregated in all the affected individuals. Thus, the co‐segregation of these three variants in genes linked with the reward pathway, in three affected members of the same family, suggests a predisposing role of this variant in the onset of AN (Bienvenu et al., [2019b](#mgg31244-bib-0012){ref-type="ref"}).

In the other study, the authors, following whole‐exome sequencing in nine female AN individuals and their parents, found seven de novo variants. Of them, four are present in genes and participate in the dopamine pathway and neuron differentiation: *CSMD1* (OMIM \*608397), *CREB3* (OMIM \*606443), *PTPRD* (OMIM \*601598), and *GAB1* (OMIM \*604,439) (Bienvenu et al., [2019a](#mgg31244-bib-0011){ref-type="ref"}).

3.2. Genome‐wide and candidate genes association studies {#mgg31244-sec-0014}
--------------------------------------------------------

Both genome‐wide (GWAS) and candidate genes association studies have revealed the genetic loci contributing to the etiology of AN.

The first two genome‐wide association studies identified an AN‐susceptibility locus on chromosome 1 (Grice et al., [2002](#mgg31244-bib-0039){ref-type="ref"}; Nakabayashi et al., [2009](#mgg31244-bib-0072){ref-type="ref"}). Further studies have identified these AN loci as opioid delta 1 receptor (OPRD1), which acts as a receptor for endogenous opioids, and serotonin 1D (HTR1D), which is a 5‐HT receptor and acts on central nervous system and affects anxiety as well as locomotion (Bergen et al., [2003](#mgg31244-bib-0008){ref-type="ref"}; Brown et al., [2007](#mgg31244-bib-0013){ref-type="ref"}).

For the further advancement and exploration of genomic study as well as genetic correlations in AN, Watson et al. conducted a genome‐wide association study including data from the Anorexia Nervosa Genetic Initiative (ANGI), the Genetic Consortium for Anorexia Nervosa (GCAN), and the Wellcome Trust Case Control Consortium‐3 (WTCCC‐3) along with UK Biobank, thus comprising 16,992 cases as well as 55,525 controls from 17 European countries. This identified eight loci encompassing the genes *NCKIPSD* (OMIM \*606671), *CADM1* (OMIM \*605686), *ERLEC1* (OMIM \*611229), *MGMT* (OMIM \*156569), *FOXP1* (OMIM \*605515), *CDH10* (OMIM \*604555), *PTBP2* (OMIM \*608449), and *NSUN3* (OMIM \*617491), which carry polymorphisms that significantly correlate with AN and metabolic/anthropometric phenotypes (Watson et al., [2019](#mgg31244-bib-0093){ref-type="ref"}).

Furthermore, according to the Gene Ontology (GO) project, one of the molecular pathways that positively regulates embryonic development and that might be associated with AN principally involves two genes, *DAG1* (OMIM \*128239) and *CTNNB1* (OMIM \*116806). *DAG1* encodes dystroglycan 1, a protein that plays an important role in connecting the extracellular matrix with the cytoskeleton, while *CTNNB1* encodes catenin β‐1, a protein that constitutes the adherens junctions and has a role in Wnt signaling (Bello et al., [2015](#mgg31244-bib-0007){ref-type="ref"}).

Another GWAS including 1,033 AN cases and 3,733 controls identified new genetic risk factors. The results of this GWAS, besides confirming the association of *OPRD1* and *HTR1D*, identified novel risk loci that showed a marginally significant association with AN: *NTNG1* (OMIM \*608818), *LRP2* (OMIM \*600073), *CDH9* (OMIM \*609974), *ZNF804B*, *VGLL4* (OMIM \*618692), and *AKAP6* (OMIM \*604691) (Wang et al., [2011](#mgg31244-bib-0092){ref-type="ref"}).

Finally, another GWAS confirmed the association of the *EBF1* (OMIM \*164343), a regulator of the adipocyte lineages development, that, when knocked out in mice, causes a reduction of adipose tissue and decrease of circulating leptin (Li et al., [2017](#mgg31244-bib-0059){ref-type="ref"}).

The involvement of serotonergic genes in the etiology of AN was investigated by candidate gene studies. For instance, the polymorphism 5‐HTTLPR (serotonin transporter‐linked polymorphic region) is a degenerate repeat polymorphic region upstream of the coding region of the *SLC6A4* (OMIM \*182138), with alleles classified as long and short based on the number of repeats. A study found that the short allele of 5‐HTTLPR is significantly associated with the increased risk of AN onset in a Chinese cohort (Chen et al., [2015](#mgg31244-bib-0017){ref-type="ref"}). In another case‐control study performed in a Mexican population, the authors found that the rs6311 polymorphism in the *HTR2A* (OMIM \*182135) gene is significantly associated with eating disorders, and individuals who are homozygous for the alternate allele have an increased risk for suicide attempts as comorbidity (Genis‐Mendoza et al., [2019](#mgg31244-bib-0034){ref-type="ref"}). This result was separately confirmed in an Italian cohort (Ceccarini et al., [2019](#mgg31244-bib-0014){ref-type="ref"}).

As mentioned above, the dopaminergic pathway regulates feeding behavior, motor activity, and reward‐motivated behavior (Chao & Nestler, [2004](#mgg31244-bib-0016){ref-type="ref"}). Thus, it is plausible that variants in the dopamine receptors might play a role in the onset of AN. In 2005, an analysis conducted in an AN cohort of polymorphisms in the *DRD2* (OMIM \*126450) gene, encoding the dopamine 2 receptor, revealed that single‐nucleotide polymorphisms (SNPs) were not significantly associated with AN. However, when those SNPs were considered as a haplotype, their association with AN became significant (Bergen et al., [2005](#mgg31244-bib-0009){ref-type="ref"}).

*BDNF* (encoding the brain‐derived neurotrophic factor) is another extensively studied candidate gene for the risk of AN. An extensive family‐based study of eight European populations consisting of 453 eating disorders (ED) trios reported an association of the Val66Met (rs6265) polymorphism with restricting subtype of AN and low minimum body mass index (BMI) (Ribasés et al., [2005](#mgg31244-bib-0077){ref-type="ref"}). According to other genetic studies, there is a 30% higher incidence of eating disorders among individuals with the Val/Met and the Met/Met polymorphism of BDNF (Gratacòs et al., [2007](#mgg31244-bib-0038){ref-type="ref"}; Mercader et al., [2007](#mgg31244-bib-0066){ref-type="ref"}). Moreover, in a recent study carried out in an Italian cohort composed of 556 ED patients and 355 negative controls, the authors demonstrated a strong association between the Met/Met genotype in AN subjects compared with the control samples (Ceccarini et al., [2019](#mgg31244-bib-0014){ref-type="ref"}).

The polymorphism rs5030980 in the Agouti‐related protein gene (*AGRP*, OMIM \*602311) that encodes an antagonist of the melanocortin‐3 and melanocortin‐4 receptors is associated with AN, whereas another SNP, rs13338499, is associated with minimum BMI in 745 AN patients (Dardennes et al., [2007](#mgg31244-bib-0025){ref-type="ref"}).

The endocannabinoid system, comprising of CB1 and CB2 receptors, contributes to the regulation of appetite and other physiological pathways linked to AN. Genetic variants in *CNR1*, such as the rs1049353 SNP, have been suggested to play a significant role in AN etiology. These findings suggest that endocannabinoids might have a fundamental role in the regulation of stable energy balance and the food intake system (Monteleone et al., [2009](#mgg31244-bib-0069){ref-type="ref"}; Wirz, Reuter, Felten, & Schwabe, [2018](#mgg31244-bib-0095){ref-type="ref"}). Several studies have reported an overrepresentation of variants in the cannabinoid receptor 1 (CNR1) in patients with AN, but these case‐control studies need to be replicated (Monteleone et al., [2009](#mgg31244-bib-0069){ref-type="ref"}). One of these studies comprised 52 family trios with single female AN patients, and four families with two affected individuals. Genetic analysis of these families revealed that the restricting and bingeing/purging subtypes of AN are associated with the eight alleles (AAT7, AAT9--15) of AAT trinucleotide repeat located downstream the coding region of the *CNR1* (Siegfried et al., [2004](#mgg31244-bib-0084){ref-type="ref"}). Another candidate gene study revealed that the microduplication at the 15q11.2 BP1 BP2 locus gives susceptibility to AN. This locus was analyzed in 1017 AN cases and 7250 controls and the results showed that *NIPA1* is one of the four non‐imprinted genes of the 15q11.2 BP1 BP2 region with the highest level of expression in the brain. *NIPA1* (OMIM \*608145) encodes a magnesium transporter protein found in endosomes and neurons. Interestingly, only microduplications of this region are associated with AN, whereas microdeletions of the same region cause excessive eating (Chang et al., [2019](#mgg31244-bib-0015){ref-type="ref"}).

The *FAAH* (OMIM \*602935) encodes the fatty acid amide hydrolase, a catabolic enzyme necessary for endocannabinoids maturation. The *FAAH* c.385C\>A SNP rs324420 elevates endocannabinoid signaling by decreasing the steady‐state levels of the FAAH protein that, in turn, leads to increased anandamide levels (Dincheva et al., [2015](#mgg31244-bib-0030){ref-type="ref"}). Monteleone et al. investigated the role of FAAH in 134 AN patients and 148 controls and confirmed that the "A" allele of rs324420 is strongly associated with a significant risk of developing AN (Monteleone et al., [2009](#mgg31244-bib-0069){ref-type="ref"}). See Table [1](#mgg31244-tbl-0001){ref-type="table"} for a summary of the SNPs found to be associated with AN.

###### 

SNPs associated with AN

  Gene        Protein                                             SNP                                                                      Reference
  ----------- --------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------
  *BDNF*      Brain‐derived neurotrophic factor                   rs6265                                                                   Ribasés et al. ([2005](#mgg31244-bib-0077){ref-type="ref"})
  *CNR1*      Endocannabinoid receptor 1                          rs1049353                                                                (Monteleone et al., [2009](#mgg31244-bib-0069){ref-type="ref"}; Wirz et al., [2018](#mgg31244-bib-0095){ref-type="ref"})
  *DRD2*      Dopamine receptor D2                                rs6275, rs6277, rs6278, rs1799732                                        Bergen et al. ([2005](#mgg31244-bib-0009){ref-type="ref"})
  *DRD4*      Dopamine receptor D4                                rs1404956473                                                             Bienvenu et al. ([2019b](#mgg31244-bib-0012){ref-type="ref"})
  *AGRP*      Agouti‐related protein                              rs5030980, rs13338499                                                    Dardennes et al. ([2007](#mgg31244-bib-0025){ref-type="ref"})
  *ESR2*      Estrogen receptor‐β                                 rs1256066, rs944050                                                      Scott‐Van Zeeland et al. ([2014](#mgg31244-bib-0081){ref-type="ref"})
  *EPHX2*     Epoxide hydrolase 2                                 rs2291635, rs1126452, rs59039594, rs1042032, rs1042064, rs4149259        Scott‐Van Zeeland et al. ([2014](#mgg31244-bib-0081){ref-type="ref"})
  *FAAH*      Fatty acid amide hydrolase                          rs324420                                                                 Monteleone et al. ([2009](#mgg31244-bib-0069){ref-type="ref"})
  *HTR1D*     Serotonin receptor                                  rs674386, rs856510, rs652783, rs604030, rs7532266                        Brown et al. ([2007](#mgg31244-bib-0013){ref-type="ref"})
  *EBF1*      EBF transcription factor 1                          rs11953630, rs9313772                                                    Li et al. ([2017](#mgg31244-bib-0059){ref-type="ref"})
  *HTR2A*     Serotonin receptor 2A                               rs6311                                                                   Genis‐Mendoza et al. ([2019](#mgg31244-bib-0034){ref-type="ref"})
  *SLC6A4*    Serotonin transporter                               rs25531                                                                  Chen et al. ([2015](#mgg31244-bib-0017){ref-type="ref"})
  *OPRD1*     Opioid receptor delta 1                             rs569356, rs204047, rs204055, rs2298896, rs521809, rs4654327, rs533123   Scott‐Van Zeeland et al. ([2014](#mgg31244-bib-0081){ref-type="ref"})
  *ZNF804B*   Zinc finger protein 804B                            rs6959888                                                                Wang et al. ([2011](#mgg31244-bib-0092){ref-type="ref"})
  *LRP2*      LDL receptor‐related protein 2                      rs830998                                                                 Wang et al. ([2011](#mgg31244-bib-0092){ref-type="ref"})
  *CDH9*      Cadherin 9                                          rs4479806                                                                Wang et al. ([2011](#mgg31244-bib-0092){ref-type="ref"})
  *VGLL4*     Vestigial like family member 4                      rs6782029                                                                Wang et al. ([2011](#mgg31244-bib-0092){ref-type="ref"})
  *AKAP6*     A‐kinase anchoring protein 6                        rs2383378                                                                Wang et al. ([2011](#mgg31244-bib-0092){ref-type="ref"})
  *NTNG1*     Netrin G1                                           rs10494067                                                               Wang et al. ([2011](#mgg31244-bib-0092){ref-type="ref"})
  *NCKIPSD*   NCK‐interacting protein with SH3 domain             rs9821797                                                                Watson et al. ([2019](#mgg31244-bib-0093){ref-type="ref"})
  *CADM1*     Cell adhesion molecule 1                            rs6589488                                                                Watson et al. ([2019](#mgg31244-bib-0093){ref-type="ref"})
  *ERLEC1*    Endoplasmic reticulum lectin 1                      rs2287348                                                                Watson et al. ([2019](#mgg31244-bib-0093){ref-type="ref"})
  *MGMT*      Methylated O6‐methylguanine‐DNA methyltransferase   rs2008387                                                                Watson et al. ([2019](#mgg31244-bib-0093){ref-type="ref"})
  *FOXP1*     Forkhead box protein P1                             rs9874207                                                                Watson et al. ([2019](#mgg31244-bib-0093){ref-type="ref"})
  *PTBP2*     Polypyrimidine tract‐binding protein 2              rs10747478                                                               Watson et al. ([2019](#mgg31244-bib-0093){ref-type="ref"})
  *CDH10*     Cadherin 10                                         rs370838138                                                              Watson et al. ([2019](#mgg31244-bib-0093){ref-type="ref"})
  *NSUN3*     NOP2/Sun RNA methyltransferase 3                    rs13100344                                                               Watson et al. ([2019](#mgg31244-bib-0093){ref-type="ref"})
  *ESRRA*     Estrogen‐related receptor alpha                     rs200039730                                                              Cui et al. ([2013](#mgg31244-bib-0021){ref-type="ref"})
  *HDAC4*     Histone deacetylase 4                               rs61754648                                                               Cui et al. ([2013](#mgg31244-bib-0021){ref-type="ref"})
  *NMS*       Neuromedin S                                        rs76201870                                                               Bienvenu et al. ([2019b](#mgg31244-bib-0012){ref-type="ref"})
  *GPR55*     G‐protein‐coupled receptor 55                       rs3749073                                                                Ishiguro et al. ([2011](#mgg31244-bib-0048){ref-type="ref"})
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3.3. Syndromes with anorexia {#mgg31244-sec-0015}
----------------------------

Anorexia can also be present in a syndromic context. In OMIM, there are five syndromes with anorexia as a feature in the clinical synopsis.

Sarcoidosis (OMIM \#181000) is a disease that mainly involves the lungs, skin, or lymph nodes, and less commonly eyes, liver, heart, and brain. Sarcoidosis is characterized by the abnormal accumulation of inflammatory cells (granulomas) around those organs. Variant haplotypes in *HLA‐DRB1* (OMIM \*142857) can confer susceptibility to this syndrome. In particular, the HLA‐DRB1\*1101 haplotype is associated with sarcoidosis. Phe47 is the amino acid residue most associated with sarcoidosis. This residue is found in the three haplotypes most associated with sarcoidosis (HLA‐DRB1\*1101, HLA‐DRB1\*1201, and HLA‐DRB1\*1501) and might have a fundamental role in peptide binding and affect T‐cell recognition (Rossman et al., [2003](#mgg31244-bib-0078){ref-type="ref"}).

Argininemia (OMIM \#207800) is caused by the deficiency of the enzyme arginase (encoded by the gene *ARG1*, OMIM \*608313) and is recessively inherited. The main symptom is the progressive accumulation of arginine and ammonia in the blood. The nervous system is particularly sensitive to the effects of excess ammonia. Patients with this syndrome might also present with anorexia and vomiting (Diez‐Fernandez, Rüfenacht, Gemperle, Fingerhut, & Häberle, [2018](#mgg31244-bib-0028){ref-type="ref"}).

Infantile hypophosphatasia (OMIM \#241500) is a recessively inherited disorder that affects the development of bones and teeth. It is caused by mutations in the *ALPL* (OMIM \*171760), which encodes an alkaline phosphatase that plays a key role in skeletal mineralization by regulating levels of the diphosphate. The signs and symptoms of hypophosphatasia vary widely. Hypophosphatasia weakens and softens the bones, causing skeletal abnormalities including short limbs, abnormally shaped chest, and soft skull bones. Additional complications include anorexia and recurrent vomiting (Weiss et al., [1988](#mgg31244-bib-0094){ref-type="ref"}).

Cyclic vomiting syndrome (OMIM \#500007) is a disorder characterized by recurrent episodes of nausea, vomiting, and lethargy. In 2003, a study on an Italian family identified a mutation (in the mitochondrial gene *MTTL1*, OMIM \*590050) co‐segregating with the phenotype in three subjects. This gene is transcribed in the leucine mitochondrial transfer RNA. The presence of recurrent vomiting and nausea can mimic the AN (Haan, Kors, & Ferrari, [2002](#mgg31244-bib-0041){ref-type="ref"}).

Distal renal tubular acidosis with hemolytic anemia (OMIM: \#611590) is a condition in which the kidneys are unable to remove enough acid from the body, making the blood too acidic. The inability to remove acids from the body results in delayed growth and softening of the bones; patients also show anorexia among their symptoms. This syndrome is caused by biallelic mutations in *SLC4A1* (OMIM +109270) that encodes a chloride/bicarbonate exchanger (Yenchitsomanus et al., [2003](#mgg31244-bib-0096){ref-type="ref"}). This protein functions as a transporter that mediates electroneutral anion exchange across the cell membrane. It is expressed in the erythrocyte where it exchanges inorganic anions across the membrane, and in the kidney where it mediates the chloride‐bicarbonate exchange required for the normal acidification of the urine (Yenchitsomanus et al., [2003](#mgg31244-bib-0096){ref-type="ref"}).

In 2015, a paper reported a 12‐year‐old female with severe anorexia and body weight loss, resembling the restricting AN. Consequently, she was first thought to have AN. However, a history of neonatal hepatitis led clinicians to suspect a citrin deficiency. Genetic analysis of *SLC25A13* (OMIM \*603859) revealed two compound heterozygous pathogenic variants and the diagnosis of citrin deficiency was confirmed (Takeuchi et al., [2015](#mgg31244-bib-0089){ref-type="ref"}).

3.4. Mouse models {#mgg31244-sec-0016}
-----------------

Mouse models are particularly important for the study of the molecular basis of AN and several genes have been found to play a key role. Animal studies on rats have established that MC4R activation decreases food intake along with the activation of the hypothalamic‐pituitary adrenal (HPA) axis and, thus, increases motor activity. These studies strongly suggest that genetic defects leading to the prolonged activation of the melanocortinergic system can potentially lead to AN (Liu, Garza, Li, & Lu, [2013](#mgg31244-bib-0060){ref-type="ref"}).

The *PMCH* (pro‐melanin‐concentrating hormone) (OMIM \*176795) encodes a prohormone precursor of melanin‐concentrating hormone (MCH), which is a hypothalamic neuropeptide. The mouse KO of *PMCH* results in a decrease in food intake, body weight, and body adiposity (Georgescu et al., [2005](#mgg31244-bib-0035){ref-type="ref"}; Shimada, Tritos, Lowell, Flier, & Maratos‐Flier, [1998](#mgg31244-bib-0083){ref-type="ref"}). Consistently, transgenic mice with increased expression of PMCH have the opposite phenotype, with hyperphagia and mild obesity (Shimada et al., [1998](#mgg31244-bib-0083){ref-type="ref"}).

The MCH1 receptor (MCH1R) is known to play a significant role in energy homeostasis by increasing locomotor activity, appetite, neuroendocrine function, and metabolic rate. MCH1R is a G protein‐coupled receptor that is responsible for MCH signal transduction. In rodents, the MCH receptor (MCH1R) is greatly expressed in the nucleus accumbens shell (AcSh), where it regulates appetite (Georgescu et al., [2005](#mgg31244-bib-0035){ref-type="ref"}). Mch1r−/− mice have a body weight within the normal range, but are lean and have a reduced fat mass. Interestingly, Mch1r−/− mice are lean because of hyperactivity and altered metabolism (Marsh et al., [2002](#mgg31244-bib-0064){ref-type="ref"}).

KO mice for the M3 muscarinic receptor gene *Chrm3* (Chrm3--/--) have decreased body weight and fat, as well as hypophagia. Even when they are injected with orexigenic agents like AGRP, they maintain a reduced feeding capacity (Yilmaz et al., [2015](#mgg31244-bib-0097){ref-type="ref"}).

*Cnr1* null mice show a significant bodyweight reduction due to reduction in food intake, although they are fed with a standard chow diet and are resistant to high‐fat obesogenic diets (Yilmaz et al., [2015](#mgg31244-bib-0097){ref-type="ref"}).

OPRD1 KO mice (Oprd1--/--) are resistant to weight gain induced by a high‐fat diet because of increased thermogenesis. Consistent with this, several studies that reported single nucleotide variants in *OPRD1* were associated with AN in humans (Czyzyk et al., [2012](#mgg31244-bib-0024){ref-type="ref"}).

Inactivation of the *Htr4* in mice causes suppression of motor hyperactivity. Consistently, stimulation of *Htr4* triggers hyperactivity and anorexia. These mice have a high rewarding effect of hyperactivity and food restriction, so that they tend to eat less and ultimately develop AN (Jean et al., [2012](#mgg31244-bib-0049){ref-type="ref"}).

The *CYFIP1* (cytoplasmic FMR1‐interacting protein 1) (OMIM \*606322) is involved in neurodevelopmental disorders. It was reported that a microduplication of the locus 15q11.2 that encompasses the *CYFIP1* is significantly associated with AN (Chang et al., [2019](#mgg31244-bib-0015){ref-type="ref"}). Not surprisingly, *CYFIP1* is one of the four paternally deleted genes in patients with type I Prader--Willi syndrome, a neurodevelopmental disorder. Type I Prader--Willi syndrome symptoms include hyperphagia, obesity, cognitive deficits, and obsessive--compulsive behaviors. Interestingly, *Cyfip1* haploinsufficiency in mice increased compulsive‐like behavior and induced genetic background‐dependent, sex‐dependent, and parent‐of‐origin‐dependent increases in palatable food intake (Babbs et al., [2019](#mgg31244-bib-0005){ref-type="ref"}). See Table [2](#mgg31244-tbl-0002){ref-type="table"} for a summary of genes mutated in mice models for AN.

###### 

Genes that when knocked‐out cause anorexia in mice. ([www.informatics.jax.org/](http://www.informatics.jax.org/))

+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| Human gene | Gene function                                                    | Knocked‐out mouse gene | Mouse features                                                                                 | Reference or MGI ID                                         |
+============+==================================================================+========================+================================================================================================+=============================================================+
| *PMCH*     | Melanin‐concentrating hormone neuropeptide                       | *Pmch*                 | Decrease of food intake, body weight, body adiposity                                           | Shimada et al. ([1998](#mgg31244-bib-0083){ref-type="ref"}) |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *CHRM3*    | Regulator of glucose homeostasis by modulating insulin secretion | *Chrm3*                | Decrease of body weight and fat mass, hypophagia                                               | Yilmaz et al. ([2015](#mgg31244-bib-0097){ref-type="ref"})  |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *CNR1*     | Orexigenic, regulation of energy expenditure                     | *Cnr1*                 | Reduction of food intake and body weight                                                       | Yilmaz et al. ([2015](#mgg31244-bib-0097){ref-type="ref"})  |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *OPRD1*    | Receptor for endogenous opioids                                  | *Oprd1*                | Resistance to weight gain, increased thermogenesis, leanness                                   | Czyzyk et al. ([2012](#mgg31244-bib-0024){ref-type="ref"})  |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *NPY2R*    | Orexigenic                                                       | *Npy2r*                | Reduction of adipose mass, increase of lean mass                                               | 108418                                                      |
|            |                                                                  |                        |                                                                                                |                                                             |
| *NPY4R*    |                                                                  | *Npy4r*                |                                                                                                | 105374                                                      |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *HCRT*     | Regulation of food intake and sleep‐wakefulness                  | *Hcrt*                 | Decreased food and water intake                                                                | 1,202,306                                                   |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *HTR4*     | Serotonin receptors                                              | *Htr4*                 | Voluntary food restriction following stress; reduction of novelty‐induced exploratory activity | Jean et al. ([2012](#mgg31244-bib-0049){ref-type="ref"})    |
|            |                                                                  |                        |                                                                                                |                                                             |
| *HTR1B*    |                                                                  | *Htr1B*                |                                                                                                |                                                             |
|            |                                                                  |                        |                                                                                                |                                                             |
| *HTR1A*    |                                                                  |                        |                                                                                                |                                                             |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *DRD1*     | Activation of pathways mediated by G protein‐coupled receptors   | *Drd1*                 | Hypophagia, locomotor deficiency                                                               | 99578                                                       |
|            |                                                                  |                        |                                                                                                |                                                             |
| *DRD2*     |                                                                  | *Drd2*                 |                                                                                                | 94924                                                       |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *DAGLA*    | Biosynthesis of 2‐arachidonoylglycerol                           | *Dagla*                | Hypophagia, decreased body weight, leanness                                                    | 2677061                                                     |
|            |                                                                  |                        |                                                                                                |                                                             |
| *DAGLB*    |                                                                  | *Daglb*                |                                                                                                | 2442032                                                     |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *NAPEPLD*  | Biosynthesis of anandamide                                       | *Napepld*              | Hypophagia, decreased body weight, leanness                                                    | 2140885                                                     |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *CCK*      | Regulation of pancreatic digestive enzymes                       | *Cck*                  | Impaired fat digestion and absorption                                                          | 88297                                                       |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *GLP1R*    | Stimulation of glucose‐induced insulin secretion                 | *Glp1r*                | Reduction of feeding behavior                                                                  | 99571                                                       |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *CRH*      | Release of hormones involved in the stress response              | *Crh*                  | Inhibition of food intake                                                                      | 88496                                                       |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
| *CYFIP1*   | FMR1‐mediated translation repression in the brain                | *Cyfip1*               | Disordered eating                                                                              | Babbs et al. ([2019](#mgg31244-bib-0005){ref-type="ref"})   |
+------------+------------------------------------------------------------------+------------------------+------------------------------------------------------------------------------------------------+-------------------------------------------------------------+
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4. MOLECULAR DIAGNOSIS {#mgg31244-sec-0017}
======================

With this paper, we intend to highlight the necessity and the urgency to develop a comprehensive genetic test for the diagnosis of AN. This need has been made clear in an editorial of The British Journal of Psychiatry (Curtis, Adlington, & Bhui, [2019](#mgg31244-bib-0023){ref-type="ref"}). The authors clearly state that there is an increasing need to understand the genetic basis of several psychiatric disorders, including AN, to establish the causes of that condition and to provide information on the recurrence risk in the relatives of AN patients. Obviously, it is still difficult to arrive at a clear answer using a genetic test in cases like AN (Curtis et al., [2019](#mgg31244-bib-0023){ref-type="ref"}).

In particular, we propose a test in which we would analyze genes involved in AN, subdivided into four groups. The first group of gene would encompass genes that have been found to carry rare variants in patients with AN for whom segregation analysis has been performed. In a second group, we would include genes associated with syndromes presenting anorexia among their main features. In a third set, we would analyze genes that have been found to carry polymorphisms conferring a higher susceptibility to the onset of AN. And finally, in the fourth group, we would include candidate genes for which mice models of AN are available.

5. DISCUSSION {#mgg31244-sec-0018}
=============

Genetic testing will give several possible benefits for the diagnosis of AN: the establishment of the recurrence risk, identification of the pathways involved in the onset of the disease, and, in the future, identification of possible treatments on the basis of the genetic background (Curtis et al., [2019](#mgg31244-bib-0023){ref-type="ref"}).

With the help of a genetic diagnostic test, most genes and SNPs involved in the primary and syndromic forms of AN could be analyzed in a single run, increasing our knowledge of the genetic background on which the environment and lifestyle factors might influence the onset of AN (Curtis et al., [2019](#mgg31244-bib-0023){ref-type="ref"}).

Presently, there are no approved drug treatments for AN. Most psychoactive drugs only give symptomatic relief to some extent, but do not offer a cure for this condition. Therefore, new and tailored treatment options are required after proper genetic diagnosis, and those options could be tested in both in vitro and in vivo models to establish their efficacy and safety profiles. Molecules that can target specific pathways might be useful for targeted treatment of AN.

For example, cannabinoid receptors are known to link hedonic response with food‐related reward processes. Interestingly, AN patients have high plasma endocannabinoid levels that suggest an impairment in the endocannabinoid system (Andries & Støving, [2011](#mgg31244-bib-0003){ref-type="ref"}). However, only one controlled trial was performed using a cannabinoid receptor agonist (tetrahydrocannabinol) in the therapy in AN patients, but this trial did not give significant results (Andries & Støving, [2011](#mgg31244-bib-0003){ref-type="ref"}). Subsequently, numerous studies were performed in patients who suffer from anorexia due to other disorders, such as cancer or AIDS, that apparently demonstrated an increase in body weight. However, the mechanisms of the onset of that kind of anorexia are quite different (Andries & Støving, [2011](#mgg31244-bib-0003){ref-type="ref"}).

Palmitoylethanolamide is synthesized from fatty acids and has been shown to bind cannabinoid receptors (Costa, Comelli, Bettoni, Colleoni, & Giagnoni, [2008](#mgg31244-bib-0020){ref-type="ref"}). Possible use of palmitoylethanolamide in the treatment of AN was recently hypothesized. In fact, while several studies suggest that palmitoylethanolamide may lead to weight loss, possibly thanks to its anti‐inflammatory effects, these anti‐inflammatory function could stabilize hypothalamic responsiveness, that, in turn, causes weight loss when the patient is obese, and weight gain when the patient is anorexic.

Another possible treatment for AN could be the use of antagonists of serotonin receptors. For instance, it is known that the stimulation of the 5‐HT4Rs activity in the brain nucleus accumbens reduces food intake and increases motor hyperactivity (Jean et al., [2012](#mgg31244-bib-0049){ref-type="ref"}). This is consistent with the observation that anorexia and motor hyperactivity are both major features of AN, suggesting a possible involvement of 5‐HT4R dysfunction in the condition. Therefore, drugs that would inhibit the activity of 5‐HT4R would be potentially useful for the treatment of AN (Leibowitz, [1990](#mgg31244-bib-0058){ref-type="ref"}).

1,25‐dihydroxyvitamin D3 is another compound that could be used for the treatment of AN. There are several studies that have found evidence for the role of 1,25‐dihydroxyvitamin D3 as a neuroprotective neurosteroid. 1,25‐dihydroxyvitamin D3 regulates calcium signaling in the brain by stimulating the expression of intracellular calcium‐binding proteins; it modulates the production of reactive oxygen species by increasing the concentrations of endogenous antioxidants in the brain and it stimulates the production of neurotrophic factors, such as the nerve growth factor, thus modulating neuronal survival and differentiation during development (Garcion et al., [1996](#mgg31244-bib-0033){ref-type="ref"}; Ibi et al., [2001](#mgg31244-bib-0047){ref-type="ref"}; Korsching, Auburger, Heumann, Scott, & Thoenen, [1985](#mgg31244-bib-0055){ref-type="ref"}). 1,25‐dihydroxyvitamin D3 might also increase the production of glial cell‐derived neurotrophic factor, necessary for the development of the dopaminergic and noradrenergic systems (Oo & Burke, [1997](#mgg31244-bib-0073){ref-type="ref"}; Quintero et al., [2004](#mgg31244-bib-0076){ref-type="ref"}). Therefore, 1,25‐dihydroxyvitamin D3 can affect cellular development in brain regions whose abnormal function is believed to be central to various psychiatric conditions, such as AN.

Additionally, other studies evaluated the potential importance of amino acid supplementation in AN. Tryptophan supplementation in the treatment of AN patients was evaluated. Tryptophan is an essential amino acid and is the immediate precursor of 5‐HT (i.e., the neurotransmitter serotonin); it has been reported that food restriction and starvation decrease tryptophan as well as serotonin levels in the brain of AN patients. Studies have shown that tryptophan supplementation boosts serotonin neurotransmission, which leads to significant therapeutic effects in AN caused by serotonin deficiency (Haleem, [2017](#mgg31244-bib-0042){ref-type="ref"}). Another study, performed in mice, showed that glutamine supplementation did not help to recover weight. However, it restores the intestinal barrier in the activity‐based anorexia mouse model (L'huillier et al., [2019](#mgg31244-bib-0057){ref-type="ref"}).

Other compounds that could be tested in AN patients might be extracted from *Panax ginseng*. In fact, its extract, called ginsenoside, has positive effects on neurological disorders through its antioxidant and immunomodulatory properties. One study showed that, along with its antioxidant activity, ginsenoside also acts as a modulator of metabolism, intracellular signaling, mitochondrial function, and apoptosis genes (Kim et al., [2018](#mgg31244-bib-0052){ref-type="ref"}). A research study has investigated the ginsenoside Rg1 effect on the ingestive behavior modulation and discovered that continuous administration of Rg1 diminished heat‐induced anorexia along with reduced ambulation and increased water intake during an environmental temperature increase. Similarly, constant infusion of Rg1, after surgically induced anorexia, prevented food intake suppression. This study showed that the rat model maintained its body weight, which indicates that constant Rg1 central administration relieves heat‐ and surgically induced anorexia (Fujimoto et al., [1989](#mgg31244-bib-0032){ref-type="ref"}).

6. CONCLUSION {#mgg31244-sec-0019}
=============

AN is a complex eating disorder in which various biological, genetic, and environmental factors contribute to the disease etiology. Hence, the relative risk for the disease susceptibility is higher in family members of AN patients than in the normal population. Candidate gene studies, as well as genome‐wide association studies, have established associations of many genetic variants with AN. Animal models are used to better understand the mechanism of onset of AN. Genome‐wide and candidate gene association studies, linkage analysis, and molecular diagnosis based on gene panels, whole exome, and genome sequencing will help to elucidate the complex genetic basis of AN and the many metabolic and molecular pathways altered in this condition, eventually providing more effective "tailored" therapeutic options for treating AN patients.
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